by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia
Abstract INTRODUCTION Anti-amyloid antibody clinical trials with a high proportion of participants reaching treatment-related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the...
by Clinical Neuropsychologist Online | Tuesday, October 6, 2026 | Dementia
Abstract INTRODUCTION People with Parkinson’s disease (PD) frequently develop dementia. We investigated the relationship between cognitive impairment and the loss of cholinergic axon projections from the nucleus basalis of Meynert to neocortical regions in PD....
by Clinical Neuropsychologist Online | Tuesday, October 6, 2026 | Dementia
Abstract BACKGROUND Our prior work demonstrated systemic P301L-tau injections in mice with mature amyloid resulted in several-fold enhancement of tauopathy compared to non-transgenic (NTg) littermates. METHODS APP+PS1 mice were injected intravenously with AAV.CAP-B10...
by Clinical Neuropsychologist Online | Tuesday, October 6, 2026 | Dementia
Abstract INTRODUCTION Cognitive impairment is a common non-motor symptom of Parkinson’s disease (PD), yet the mechanism remains unclear. METHODS Longitudinal serum samples from PD patients in a community-based case–control study were profiled, with cognition...
by Clinical Neuropsychologist Online | Tuesday, October 6, 2026 | Dementia
Abstract INTRODUCTION To optimize a model of amyloid-enhanced tauopathy we compared wild-type (WT) tau with P301L-tau in a mouse with mature amyloid. METHODS Mice transgenic for amyloid precursor protein and presenilin-1 (APP+PS1, A/P) were injected intravenously with...
